ArunA Biomedical, Inc.
425 River Road
16 articles with ArunA Biomedical, Inc.
Dr. Steven Stice to Continue Leading Company’s Research and Manufacturing Operations
ArunA Biomedical today announced that Steven Stice, Ph.D., co-founder, chief executive and chief scientific officer, will present a corporate update and participate on a panel at the 2018 BIO International Convention occurring June 4-7, 2018 in Boston, MA.
ArunA Biomedical announced it will present data at the 2018 International Society for Extracellular Vesicles (ISEV) Annual Meeting occurring May 2-6 in Barcelona, Spain.
ArunA Biomedical Announces Publication of Study in Stroke that Reports Exosomes Improved Tissue and Functional Recovery in Pig Model of Ischemic Stroke
First company to demonstrate proof-of-concept of the therapeutic potential of extracellular vesicles in two divergent animal species and two stroke types
ArunA Biomedical Launches New Class of Exosome Biologics to Treat Central Nervous System and Neurodegenerative Disorders
With an initial focus on an exosome therapeutic for stroke, the company published results of a study today in Translational Stroke Research that found extracellular vesicles (EVs) derived from human neural stem cells improved tissue and functional recovery in murine thromboembolic stroke models.
Aruna Biomedical, Inc. Announces Product Manufacturing and Distribution Agreement With Life Technologies
Aruna Biomedical, Inc. Awarded Department of Defense Contract to Further Develop Environmental Biosensor for National Security
Aruna Biomedical, Inc. Announces Commercial Release of its Human Embryonic Stem Cell Derived Mesenchymal Cells
Aruna Biomedical, Inc. Announces Alliance with Neuromics, Inc. for Distribution of Normal Human Neural Cells
Aruna Biomedical, Inc. Announces Commercial Release of its Human Embryonic Stem Cell Derived Neural Cells
Aruna Biomedical, Inc. Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
Aruna Biomedical, Inc. Announces Technology Licensing Agreement To Commercialize The First Products Derived From Human Embryonic Stem Cells